Exscientia expands international collaborations with AI drug discovery partnership with GT Apeiron Therapeutics
LONDON: Frontier IP’s portfolio company Exscientia, a world leader in artificial intelligence (AI) drug discovery, has entered into a drug-discovery partnership with GT Apeiron Therapeutics. GT Apeiron is a Shanghai-headquartered…